Clinical effectiveness and cost effect analysis of quadrivalent HPV vaccine

Abstract

1 ABSTRACT Quadrivalent Human Papillomavirus Vaccine- Evaluation of clinical effectiveness and national vaccine programs Author: Nataša Lekić Research Advisor: PharmDr. Lenka Práznovcová, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague. SUMMARY QUADRIVALENT HPV VACCINE- EVALUATION OF CLINICAL EFFECTIVENESS AND NATIONAL VACCINE PROGRAMS Background: Human papillomavirus types 6, 11,16 and 18 cause majority of genital warts and cervical cancer. Recent manufacture of quadrivalent HPV vaccine is an intent to prevent and reduce morbidity and mortality. Aim of Study: The aim of this summarized study is the evaluation of effectiveness, safety and the economical value of quadrivalent HPV 6/11/16/18 vaccine (Gardasil/Silgard) manufactured by Merck co. Recommendations for successful national vaccination programs. Methods: The study was performed using bibliographical investigation of various scientific databases, government publications and manufacturer's publications. Results: Current quadrivalent HPV vaccine has been shown to be efficient and safe in clinical trials. Several components are needed to be assessed for successful vaccination programs including: government will and financial support, education of the public, vaccination cost and...